Back to top
more

La Jolla Pharmaceutical Company (LJPC)

(Delayed Data from NSDQ)

$8.26 USD

8.26
455,799

+0.22 (2.74%)

Updated May 3, 2019 04:00 PM ET

After-Market: $8.27 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[LJPC]

Reports for Purchase

Showing records 61 - 72 ( 72 total )

Industry: Medical - Drugs

Record: 61

06/05/2014

Daily Note

Pages: 5

Enrollment Completed for Phase 2 Extension Study of GCS-100 in CKD; Reiterate OUTPERFORM and $34 Price Target

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 62

06/05/2014

Daily Note

Pages: 5

Enrollment Completed for Phase 2 Extension Study of GCS-100 in CKD; Reiterate OUTPERFORM and $34 Price Target

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 63

06/02/2014

Daily Note

Pages: 47

June and 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 64

05/21/2014

Industry Report

Pages: 47

Emerging Pharmaceuticals - May and 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 65

05/21/2014

Industry Report

Pages: 47

May and 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 66

05/01/2014

Company Report

Pages: 7

Q1 Financials Had No Surprises; Cash Runway to YE Covers Material Catalysts. Reiterate OUTPERFORM & Increasing PT to $34 for Time Value.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 67

04/09/2014

Daily Note

Pages: 46

April and 2014 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 68

04/04/2014

Company Report

Pages: 7

2013 Financials: Cash Runway to YE Covers Additional GCS-100/CKD & LJPC-501/HRS Clinical Data Releases.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 69

03/10/2014

Company Report

Pages: 7

GCS-100 Phase 2a CKD Trial Results Were Positive. Reiterate OUTPERFORM and Increasing PT to $32.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 70

03/05/2014

Daily Note

Pages: 5

GCS-100 Phase 2 Results for CKD Expected After Market Close on March 10th. Reiterate OUTPERFORM and $27 Price Target.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 71

03/05/2014

Daily Note

Pages: 5

GCS-100 Phase 2 Results for CKD Expected After Market Close on March 10th. Reiterate OUTPERFORM and $27 Price Target.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 72

02/25/2014

Company Report

Pages: 21

Initiating Coverage with an OUTPERFORM Rating and $27 Price Target; Experienced Management, Attractive Pipeline, Plus a Near-Term Clinical Catalyst

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party
// eof